Betaferon Use in Children and Adolescents With Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-01

Study Completion Date

2009-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine efficacy, safety and tolerability of interferon beta-1b for multiple sclerosis (MS) in children and adolescents

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

NCT00963833

Multiple Sclerosis

COMPLETED

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00206635

Multiple Sclerosis

COMPLETED

Depression and Fatigue in MS Patients Treated With Betaferon.

NCT01354665

Multiple Sclerosis

COMPLETED

Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon

NCT01766063

Multiple Sclerosis

COMPLETED

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

NCT01031459

Multiple Sclerosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients treated with Betaferon

Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.

Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)

Intervention Type DRUG

Betaferon was injected subcutaneously as prescribed by the treating physician.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)

Betaferon was injected subcutaneously as prescribed by the treating physician.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with symptoms consistent with the diagnosis of a demyelinating CNS disease
* patients who received at least one injection of Betaferon before age 18 (before their 18th birthday)
* recorded use of at least one dose of Betaferon before January 1, 2008